ADAM-17: a novel therapeutic target for triple negative breast cancer

Validated targeted therapy is currently unavailable for patients with invasive breast cancer negative for oestrogen receptors, progesterone receptors and HER2 [i.e., those with triple-negative (TN) disease]. ADAM-17 is a protease involved in the activations of several ligands that bind to and promot...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2013-02, Vol.24 (2), p.362-369
Hauptverfasser:	McGowan, P.M., Mullooly, M., Caiazza, F., Sukor, S., Madden, S.F., Maguire, A.A., Pierce, A., McDermott, E.W., Crown, J., O'Donovan, N., Duffy, M.J.
Format:	Artikel
Sprache:	eng
Schlagworte:	ADAM Proteins - antagonists & inhibitors ADAM Proteins - biosynthesis ADAM Proteins - metabolism ADAM17 ADAM17 Protein Antineoplastic agents Biological and medical sciences Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Cell Line, Tumor Cell Proliferation - drug effects Cell Survival - drug effects ErbB Receptors - metabolism Female Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Molecular Targeted Therapy Pharmacology. Drug treatments Phosphorylation - drug effects Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism RNA, Messenger - biosynthesis Signal Transduction - drug effects therapeutics Transforming Growth Factor alpha - metabolism triple-negative breast cancer Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!